BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Keam SJ. Doripenem: A Review of its Use in the Treatment of Bacterial Infections. Drugs 2008;68:2021-57. [DOI: 10.2165/00003495-200868140-00007] [Cited by in Crossref: 43] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Jones RN, Bell JM, Sader HS, Turnidge JD, Stilwell MG. In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens. Diagnostic Microbiology and Infectious Disease 2009;63:434-9. [DOI: 10.1016/j.diagmicrobio.2009.01.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
2 Nandy P, Samtani MN, Lin R. Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients. Antimicrob Agents Chemother 2010;54:2354-9. [PMID: 20385854 DOI: 10.1128/AAC.01649-09] [Cited by in Crossref: 36] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
3 Oelschlaeger P, Ai N, Duprez KT, Welsh WJ, Toney JH. Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm? J Med Chem 2010;53:3013-27. [PMID: 20121112 DOI: 10.1021/jm9012938] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
4 Kaniga K, Flamm R, Tong SY, Lee M, Friedland I, Redman R. Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. Antimicrob Agents Chemother. 2010;54:2119-2124. [PMID: 20211892 DOI: 10.1128/aac.01450-09] [Cited by in Crossref: 30] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
5 Breilh D, Texier-maugein J, Allaouchiche B, Saux M, Boselli E. Carbapenems. Journal of Chemotherapy 2013;25:1-17. [DOI: 10.1179/1973947812y.0000000032] [Cited by in Crossref: 44] [Cited by in F6Publishing: 19] [Article Influence: 4.9] [Reference Citation Analysis]
6 Testero SA, Fisher JF, Mobashery S. β‐Lactam Antibiotics. Burger's Medicinal Chemistry and Drug Discovery. Wiley; 2003. pp. 257-402. [DOI: 10.1002/0471266949.bmc226] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Endimiani A, Perez F, Bajaksouzian S, Windau AR, Good CE, Choudhary Y, Hujer AM, Bethel CR, Bonomo RA, Jacobs MR. Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility. J Clin Microbiol 2010;48:4417-25. [PMID: 20881179 DOI: 10.1128/JCM.02458-09] [Cited by in Crossref: 36] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
8 Martín-lópez A, Castaño-ávila S, Maynar-moliner FJ, Urturi-matos JA, Manzano-ramírez A, Martín-lópez HP. Peritonitis terciaria: tan difícil de definir como de tratar. Cirugía Española 2012;90:11-6. [DOI: 10.1016/j.ciresp.2010.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
9 Cattoir V, Daurel C. [Update on antimicrobial chemotherapy]. Med Mal Infect 2010;40:135-54. [PMID: 19959306 DOI: 10.1016/j.medmal.2009.10.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
10 Fritsche TR, Sader HS, Stillwell MG, Jones RN. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003–2007). Diagnostic Microbiology and Infectious Disease 2009;63:440-6. [DOI: 10.1016/j.diagmicrobio.2009.01.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
11 Yamamiya A, Kitamura K, Ishii Y, Sato Y, Iwata T, Nomoto T, Honma T, Yoshida H. Usefulness of Continuous Regional Arterial Infusion with Doripenem and Protease Inhibitors for Severe Acute Pancreatitis. Showa Univ J Med Sci 2015;27:29-37. [DOI: 10.15369/sujms.27.29] [Reference Citation Analysis]
12 Zhanel GG, Ketter N, Rubinstein E, Friedland I, Redman R. Overview of Seizure-Inducing Potential of Doripenem: . Drug Safety 2009;32:709-16. [DOI: 10.2165/00002018-200932090-00001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
13 Fujisaki M, Sadamoto S, Hishinuma A. Evaluation of the double-disk synergy test for New Delhi metallo-β-lactamase-1 and other metallo-β-lactamase producing gram-negative bacteria by using metal-ethylenediaminetetraacetic acid complexes. Microbiol Immunol 2013;57:346-52. [PMID: 23668606 DOI: 10.1111/1348-0421.12042] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
14 Levi ME, Eusterman VD. Oral infections and antibiotic therapy. Otolaryngol Clin North Am 2011;44:57-78, v. [PMID: 21093623 DOI: 10.1016/j.otc.2010.10.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
15 Tazuma S, Igarashi Y, Inui K, Ohara H, Tsuyuguchi T, Ryozawa S; BTI Therapy Research Group. Clinical efficacy of i.v. doripenem, a new class of carbapenem, in patients with biliary tract infection: A multicenter trial. Hepatol Res 2011;41:340-9. [PMID: 21426451 DOI: 10.1111/j.1872-034X.2011.00783.x] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
16 Karageorgopoulos DE, Falagas ME. New antibiotics: optimal use in current clinical practice. International Journal of Antimicrobial Agents 2009;34:S55-62. [DOI: 10.1016/s0924-8579(09)70569-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
17 Cielecka-piontek J, Jelińska A, Dołhań A, Zalewski P. Kinetic and thermodynamic analysis of degradation of doripenem in the solid state: Kinetic and Thermodynamic Analysis of Degradation of Doripenem. Int J Chem Kinet 2012;44:722-8. [DOI: 10.1002/kin.20722] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
18 Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. J Antimicrob Chemother. 2010;65 Suppl 3:iii25-iii33. [PMID: 20876625 DOI: 10.1093/jac/dkq298] [Cited by in Crossref: 63] [Cited by in F6Publishing: 74] [Article Influence: 5.7] [Reference Citation Analysis]
19 Nakamura K, Ikawa K, Yamada Y, Arakawa M, Zennami K, Nishikawa G, Ikeda K, Morikawa N, Honda N. Determination of doripenem penetration into human prostate tissue and assessment of dosing regimens for prostatitis based on site-specific pharmacokinetic-pharmacodynamic evaluation. J Chemother 2012;24:32-7. [PMID: 22546722 DOI: 10.1179/1120009X12Z.0000000007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Garazzino S, Lutsar I, Bertaina C, Tovo P, Sharland M. New antibiotics for paediatric use: A review of a decade of regulatory trials submitted to the European Medicines Agency from 2000—Why aren’t we doing better? International Journal of Antimicrobial Agents 2013;42:99-118. [DOI: 10.1016/j.ijantimicag.2013.05.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
21 Jaruratanasirikul S, Wongpoowarak W, Kositpantawong N, Aeinlang N, Jullangkoon M. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia. Int J Antimicrob Agents 2012;40:434-9. [PMID: 22959555 DOI: 10.1016/j.ijantimicag.2012.07.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
22 Lo TS, Borchardt SM, Welch JM, Rohrich MA, Alonto AM, Alonto AV. Doripenem in hospital infections: a focus on nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infections. Infect Drug Resist 2009;2:41-9. [PMID: 21694886 DOI: 10.2147/idr.s4083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Martínez MJ, García MI, Sánchez EG, Sánchez JE. [Available carbapenems: Properties and differences]. Enferm Infecc Microbiol Clin 2010;28 Suppl 2:53-64. [PMID: 21130931 DOI: 10.1016/S0213-005X(10)70031-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
24 Iimaa T, Hirayama T, Shirakigawa N, Imai D, Yamao T, Yamashita YI, Baba H, Ijima H. Antibacterial-Agent-Immobilized Gelatin Hydrogel as a 3D Scaffold for Natural and Bioengineered Tissues. Gels 2019;5:E32. [PMID: 31212711 DOI: 10.3390/gels5020032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
25 Balderson BJ, Yates ME, Patil NP, Suda KJ. Evaluation of doripenem utilization and susceptibilities at a large urban hospital. Int J Clin Pharm 2011;33:958-63. [PMID: 21984226 DOI: 10.1007/s11096-011-9567-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Ye L, Zhang J, Xiao W, Liu S. Efficacy and mechanism of actions of natural antimicrobial drugs. Pharmacol Ther 2020;216:107671. [PMID: 32916205 DOI: 10.1016/j.pharmthera.2020.107671] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Dhillon RH, Clark J. ESBLs: A Clear and Present Danger? Crit Care Res Pract 2012;2012:625170. [PMID: 21766013 DOI: 10.1155/2012/625170] [Cited by in Crossref: 42] [Cited by in F6Publishing: 55] [Article Influence: 3.8] [Reference Citation Analysis]
28 Tazuma S, Igarashi Y, Inui K, Ohara H, Tsuyuguchi T, Ryozawa S; BTI Therapy Research Group. Clinical efficacy of intravenous doripenem in patients with acute biliary tract infection: a multicenter, randomized, controlled trial with imipenem/cilastatin as comparator. J Gastroenterol 2015;50:221-9. [PMID: 24795092 DOI: 10.1007/s00535-014-0960-0] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
29 Pankuch GA, Seifert H, Appelbaum PC. Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Diagn Microbiol Infect Dis 2010;67:191-7. [PMID: 20338710 DOI: 10.1016/j.diagmicrobio.2010.01.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
30 Alvarez-Lerma F, Grau S, Ferrández O. Characteristics of doripenem: a new broad-spectrum antibiotic. Drug Des Devel Ther 2009;3:173-90. [PMID: 19920933 DOI: 10.2147/dddt.s3083] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
31 Yamada Y, Ikawa K, Nakamura K, Mitsui K, Narushima M, Hibi H, Ikeda K, Morikawa N, Honda N. Penetration of doripenem into prostatic tissue following intravenous administration in prostatectomy patients. International Journal of Antimicrobial Agents 2010;35:504-6. [DOI: 10.1016/j.ijantimicag.2010.01.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]